FDA’s New PreCheck Program Aims to Speed Construction of US Drug Manufacturing - news.constructconnect.com
FDA's new PreCheck Program aims to expedite the construction of drug manufacturing facilities, enhancing the approval process for new drug applications.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. All pharmaceutical manufacturers planning to construct new facilities or expand existing ones. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Introduction of a PreCheck Program to streamline the construction and approval process for drug manufacturing.
Who it affects
All pharmaceutical manufacturers planning to construct new facilities or expand existing ones.
What you must do
Engage with the FDA to understand how to leverage the PreCheck Program for upcoming construction projects.
Deadline
Not specified.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- The FDA just cleared the way for drug importation. What now? - politico.com
- EPA names BD, Edwards and Medtronic on list of higher-risk sterilization facilities - MedTech Dive
- COVID-19 vaccines may be harder to get in Kentucky under new FDA guidelines. Here's why - The Courier-Journal
- Greek national indicted for selling counterfeit and unapproved prescription drugs to internet pharmacies and undercover agents - justice.gov
- Pfizer Kansas plant hit by FDA 483 with 8 repeat observations - bioprocessintl.com